Immunization against Pertussis: An Almost Solved Problem or a Headache in Public Health by Dias, Waldely de Oliveira et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Immunization against Pertussis: An Almost Solved
Problem or a Headache in Public Health
Waldely de Oliveira Dias, Ana Fabíola R.O. Prestes,
Priscila S. Cunegundes, Eliane P. Silva and Isaias Raw
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69283
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Waldely de Oliveira Dias, Ana Fabíola R.O. 
Prestes, Priscila S. Cunegundes, Eliane P. Silva 
and Isaias Raw
Additional information is available at the end of the chapter
Abstract
Whooping cough or pertussis is a serious infectious disease of the human respi-
ratory tract, caused by Gram-negative bacteria Bordetella pertussis and Bordetella 
 parapertussis
HU
. The current pertussis vaccines may consist of dead cells of B. pertus-
sis (whole cell pertussis vaccines—wPs) or purified antigens from the bacterium 
(acellular pertussis vaccines—aPs). The aPs are less reactogenic and have been 
widely used in developed countries for more than two decades, but their high cost 
of production makes them prohibitive for developing countries, and the accelerated 
rate of epidemic outbreaks has led to the hypothesis that aPs are less effective than 
the wP ones. Considering cost-effectiveness, some authors have pointed out ques-
tions about the possibility of reintroduction of wP vaccines into the primary doses 
of pertussis vaccination. The Butantan Institute in São Paulo, Brazil, developed a wP 
vaccine with low endotoxicity (Plow) obtained by chemical extraction of the lipooli-
gosaccharide (LOS) fraction from the outer membrane of the bacterial cell, showing 
to be less reactogenic and equally immunogenic and protective as the traditional 
wP vaccine. The Plow may possibly be introduced into the vaccination schedule for 
immunization of adolescents and young adults in Brazil, an important epidemio-
logical contribution to reducing the circulation of B. pertussis.
Keywords: pertussis, Bordetella pertussis, whole cell pertussis vaccine, acellular pertussis 
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1. Introduction
Pertussis or whooping cough is an acute and serious infectious disease of the respiratory 
tract, directly transmitted from human to human through respiratory aerosols [1]. The 
World Health Organization (WHO) estimates the annual incidence of 16 million cases of 
pertussis, with 195,000 deaths per year, one of the main causes of mortality for vaccine-
preventable diseases in children less than five years [2, 3]. The main causative agent is 
the Gram-negative bacterium Bordetella pertussis, but although Bordetella parapertussis
HU
 
leads to a milder disease [4, 5], it has also been associated with more severe episodes, 
such as pneumonia and bronchopneumonia in children, with possible lethal conse-
quences [6, 7]. The disease is exclusively human, with characteristics that differentiate it 
from other respiratory diseases [8, 9] and was widely disseminated in pre-vaccine era, 
mainly affecting children from 1 to 9 years of age. [10]. There is evidence that B. pertussis 
and B.  parapertussis
HU
 were adapted to restricted niches of hosts, which possibly allowed a 
more effective infection [11–14]. Pertussis toxin (PT), considered the main virulence factor 
of B. pertussis, is not produced by B. parapertussis, where the PT gene is transcriptionally 
silent [5, 15], which could be a reason for the frequently milder symptoms following infec-
tion by B.  parapertussis [4, 5, 16, 17].
The classical manifestations of pertussis are divided into three phases: catarrhal, paroxys-
mal, and convalescent [18], and are particularly serious in unprotected newborns and young 
infants (<1 year old), with bacteria disseminating into the lungs causing necrotizing bron-
chiolitis, intra-alveolar hemorrhage, and fibrinous edema. In the most severe cases, there is 
usually intense lymphocytosis, correlated with pulmonary hypertension, respiratory fail-
ure, and death [19]. Older children, adolescents, and adults can also be affected [20], and 
although in these age groups the clinical manifestations may vary from the classic symptoms 
to moderate or even absent cough [21], high rates of the bacteria have been found in this 
population [9], who act as reservoirs and can transmit the infection to at-risk groups, such as 
neonates and infants [22].
2. Pertussis vaccines: an almost solved problem?
The initial attempts to develop a vaccine against B. pertussis occurred in a completely 
empirical way, after the culture of this bacterium in the laboratory by Jules Bordet and 
Octave Gengou, of the Pasteur Institute in Brussels in 1906 [23]. The first effective pertus-
sis vaccine was developed in the 1930s by Pearl Kendrick and Grace Eldering using killed 
whole B.  pertussis cells [24]. The introduction of such whole cell pertussis vaccines (wPs) 
in the late 1940s, right after combined with the diphtheria and tetanus toxoids for the for-
mulation of the triple bacterial vaccine (DTP) [25], greatly reduced the incidence of the 
disease [9], leading to its almost eradication in the early 1970s [10]. However, although 
effective, wPs were associated with undesirable side effects, which led to a decrease in 
the acceptance of these vaccines and the rapid increase of pertussis incidence in several 
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countries [26, 27]. In Great Britain, by 1977, the vaccination coverage rate for pertussis fell 
from 77 to 33%, and up to 9%, in some  districts [28]. In Japan, the government suspended 
pertussis vaccination in February 1975, due to widespread publicity of two deaths in chil-
dren, allegedly related to the vaccine, leading to a whopping cough peak two years later, 
accounting for 13,000 reported cases and 40 deaths [29, 30]. The reactogenicity of wPs was 
extensively evaluated in DTP, and the pertussis component proved to be mainly respon-
sible for the toxicity of these combined vaccines. Summarizing the findings from these 
analyses, some authors report a prospective study conducted in Los Angeles from January 
1978 to December 1979 in children of 0–6 years old, involving 15,752 doses of DTP and 784 
doses of DT. The children were evaluated for local and systemic reactions occurring within 
48 hours of immunization. Overall, all local and systemic reactions were significantly more 
frequent in children who had taken DTP vaccine than DT. At the site of application, red-
ness, swelling, and pain occurred in 37.4, 40.7, and 50.9%, respectively, in those receiving 
DTP, but only 7.6, 7.6, and 9.9%, respectively, in those who received DT. The percentage of 
these reactions in DTP vaccinated increased from the first to the fifth dose [9].
The global consequence of the refusal to accept the wP vaccines resulted in the development 
of the first acellular pertussis vaccine (aP), the Japanese vaccine of Sato et al. [31], containing 
purified antigens from the bacterium. As there was an ongoing pertussis epidemic at that 
time, DTaP vaccines were very rapidly developed in Japan and immediately incorporated 
into their vaccine calendar in 1981 [32, 33]. In the late 1990s, the wPs were gradually replaced 
by aPs in many developed countries [34]. Current aP vaccines contain 1–5 purified pertussis 
proteins: inactivated PT, filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae 2 
and 3 [35].
Nowadays, DTP vaccines are available in various formulations, containing whole cell (wP) 
or acellular (aP) pertussis component combined with diphtheria toxoid (D/d) and tetanus 
toxoid (T) to produce either full-strength— diphtheria/tetanus/wP (DTwP) or aP (DTaP) 
vaccines—or reduced antigen-content (Tdap) vaccines, which are used for primary (DTwP 
or DTaP) or booster (Tdap) immunization. Whole cell pertussis vaccines are not indicated 
for individuals over seven years of age, and WHO only recommends formulations with 
lower concentrations of diphtheria toxoid and pertussis (Tdap and Td) in order to reduce 
their reactogenicity [36, 37]. More recently, DTP is presented as the basis for combined vac-
cines containing additional antigens added alone or in combinations, such as Haemophilus 
influenzae type b (Hib), hepatitis B, and inactivated poliovirus [38–43], allowing the admin-
istration of multiple vaccine antigens in a single injection, leading to the induction of simul-
taneous immunity for multiple diseases [44, 45]. These combined vaccines were approved 
by the World Health Organization’s Expanded Program on Immunization (EPI) [46–48], 
which substantially reduced the number of injections required in the childhood vaccine 
schedule. Clinical studies using the DTPa-HBV-IPV/Hib hexavalent vaccine have shown 
that it is safe and effective [45, 49], and the incidence of local and systemic adverse reac-
tions was comparable to those observed after administration of single vaccines or other 
DTaP-based vaccines [50–53], always less reactogenic than the combinations using whole 
cell pertussis vaccine (DTPw) [52].
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3. Pertussis resurgence: a multifactorial problem
The preliminary clinical trials comparing DTaP with DTwP in the 1990s suggested compa-
rable efficacy and immunogenicity [54–58]. However, more recent data have shown that 
the disease is not adequately controlled and outbreaks have occurred, even in countries 
with extensive vaccine coverage [59–61]. The reasons for the apparent ineffectiveness of 
current vaccines and vaccination programs in the control of infection and transmission 
are unclear, but there are likely to be a number of factors contributing to the short-lived 
immunity after vaccination [62–64]. DTaP vaccines were licensed and recommended as 
a booster in the USA in 1992 and introduced as primary immunization in newborns in 
1997. Currently, even with 95% vaccine coverage in newborns and use of booster dose in 
adolescents, pertussis is the least immunopreventable disease, with the highest incidence 
rates already reported in the post-vaccination era [65]. Possible reasons for the resurgence 
of pertussis include a reduction in vaccine efficacy, with rapid waning immunity, improve-
ment in the epidemiological surveillance and diagnostic methods, and genetic changes in 
the pathogen [66].
DTaP vaccination induces excellent, but not durable, immune response [67–69]. The higher 
antigenic load of the wPs may explain the epidemiological evidence that supports the longer 
lasting protection induced by these vaccines, in relation to the aPs. Potentially protective anti-
gens may be absent or may be in insufficient quantity in the aP formulations, or may exhibit 
poor cross-match with antigens present in the circulating bacterial strains [70]. The immunity 
conferred by DTaP drops every year after the fifth dose, so that 5 years after the last dose the 
probability of a child vaccinated with this vaccine to acquire the disease is four to fifteen times 
greater than that after the initial doses [63, 64, 71, 72], and 80% of these children are no longer 
protected at the time of Tdap booster [73]. The efficacy conferred by Tdap was 75.3% in a per-
tussis outbreak in Wisconsin in 2012, falling after 2 years to 34.5% [74].
Differences between wP and aP vaccines, related to its antigenic load and presentation of 
antigens to antigen presenting cells, lead to a different balance of Th1/Th2/Th17 response. 
The role of Th1 and Th17 cells has been demonstrated in the protective immunity induced by 
B. pertussis infection or immunization with wP, and on the other hand, immunization with 
an aP vaccine administered with alum as adjuvant induced Th2 and Th17 cells, but poor Th1 
response [75]. The multiple virulence factors of B. pertussis, many of them efficiently main-
tained in the wP vaccines, presuppose a better stimulation of innate immunity, leading to the 
generation of effective Th1/Th17-skewed adaptive immunity [76].
The probability of contracting the disease of humans primed with DTwP is lower than those 
primed with DTaP [62, 63, 68, 69]. Adolescents vaccinated with three doses of DTaP were 
3.3 times more likely to contract pertussis than children vaccinated only with DTwP [46, 62]. 
These data were recently confirmed in baboons, an animal model that reproduces the char-
acteristics of human infection [77–79]. Baboons immunized with DTaP and challenged with 
a clinical isolate of B. pertussis are heavily colonized and do not control the infection until 
4–5 weeks, transmitting the bacteria to naive animals. Those vaccinated with DTwP are colo-
nized, but without leukocytosis, and control the infection in 2–3 weeks, faster than those not 
previously vaccinated [78].
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There is evidence that circulating strains of B. pertussis are evolving to evade the vaccine-
conferred immunity [80]. In fact, pertactin-deficient B. pertussis strains were identified in 
85% of the isolates obtained from eight US states between 2011 and 2013 [81]. These samples 
emerged rapidly and did not express the PRN contained in the DTaP vaccine, and suggesting 
selective advantage, individuals previously vaccinated against pertussis had higher chance of 
infection with the PRN-deficient strains than with the strain expressing that protein [82–85]. 
Besides that, an increase in the incidence of vaccine alleles of B. pertussis could also suggest an 
evolutionary epitope-mediated vaccine pressure [86–89], contributing to the reemergence of 
pertussis in humans, and in this sense, it is also not clear how the B. parapertussis can answer 
to the selective pressure exerted by large-scale vaccination against B. pertussis.
Although highly effective in reducing the incidence of pertussis infections, the acellular per-
tussis vaccines have little or no efficacy against B. parapertussis [17, 90, 91]. Some authors have 
postulated that vaccination with aPs can interfere with the “clearance” of B. parapertussis, 
facilitating the adaptive performance of this pathogen, which could lead to the emergence 
of more susceptible hosts to B. parapertussis infection [92]. Accordingly, a gradual increase in 
the prevalence of B. parapertussis has been observed as a result of epidemiological pertussis 
immunization with vaccines that are less protective against B. parapertussis than the natural 
infection with B. pertussis [93]. Similar to the serum specificity observed in other infectious 
diseases, pertussis vaccines may have led to epidemiological pressure, with an increase in the 
prevalence of B. parapertussis. Since the differential diagnosis would not affect clinical proce-
dures, the vast majority of pertussis studies are not directed to the identification of B. paraper-
tussis, which probably has led to unreported cases. However, studies aimed at the differential 
diagnosis showed that B. parapertussis comprise from 2 to 36% of the cases [94].
In August 2015, the World Health Organization published its position on pertussis vac-
cines [95], in an attempt to provide substantiated information for immunization and public 
health programs, in a document that replaces the previous one published in 2010 [35]. The 
main goal of this position paper was to guide the choice of pertussis vaccines—wP or aP—to 
the most current strategies to reduce the risk of pertussis in infants and young children. In this 
document, it was established that the goal to be achieved in all countries is the maintenance 
of high vaccination coverage (higher than 90%). High levels of safety and protection can be 
obtained by the wP and the aP vaccines, after the primary series of immunization with three 
doses, ideally completed by the sixth month of life (Table 1). However, although systemic and 
local reactions are more commonly associated with wP, the duration of protection conferred 
by these vaccines is longer [96–98]. The pertussis vaccination schedule should maintain pro-
tection for at least six years in countries using wP, but the protection may suffer a marked 
decline before the age of six years when aP is used (Table 1) [95]. Vaccination of pregnant 
women has been recommended by WHO as the best strategy for disease prevention in infants 
too young to be vaccinated or with incomplete immunization schedule, and the change from 
wP to aP in primary immunization should only be considered in countries that are able to 
maintain a schedule with periodic reinforcement and sustainable maternal immunization. 
If this is not the case, immunization with wP should be maintained and in national programs 
using aP, consideration should be given to the introduction of additional booster doses in 
the case of pertussis reemergence [95]. The production cost of the aP vaccine is considerably 
higher than that of the wP (difference of more than 5 US$ per dose with PAHO’s revolving 
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fund price), which has a direct implication in health systems, especially in underdeveloped 
and developing countries.
Considering cost-effectiveness in the implementation of national vaccination programs, some 
authors have pointed out questions about the possibility of reintroduction of wP vaccines into 
the primary doses of pertussis vaccination [76, 99, 100], which could again lead to the prob-
lems with the reactogenicity of these vaccines.
4. Back to the past: whole cell pertussis vaccine as a new alternative
In Brazil, mandatory notification of all outbreaks began in 1975 when the pertussis entered 
the list of notifiable diseases. In the early 1980s, more than 40,000 cases were reported 
per year, with an incidence rate >30/100,000 inhabitants. With the introduction of the DTP 
vaccine in the Brazilian scheme of childhood vaccination in 1983, this number fell sharply 
[101]. In 2002, the first three doses of the DTwP were replaced by the tetravalent vaccine 
DTwP + H. influenzae type B (DTwP-Hib), that in 2012 was replaced by the pentavalent 
DTwP + H. influenzae type B + hepatitis B (DTwP-Hib-HBV). The first three doses of the pen-
tavalent vaccine are administered at 2, 4, and 6 months of age, followed by DTwP booster 
at 15 and 48 months of age. DTaP vaccine is recommended for children at increased risk 
of developing or who have developed severe adverse events to the DTwP, and the vaccine 
is available at the Special Immunobiological Reference Centers. After 2014 the Brazilian 
National Immunization Program began to offer Tdap to pregnant women [102]. Despite 
the high vaccination coverage (>95%) since 2011, a significant increase in the number of 
reported cases of pertussis in Brazil has been observed, with an incidence rate in 2013 of 
14,058 confirmed cases/100,000 in infants under one year of age, the majority of cases and 
deaths in unvaccinated children younger than 4 months old [103].
The Butantan Institute in São Paulo, Brazil, produces DTwP vaccine since 1953. Currently, 
more than 90% of Brazilian children are vaccinated at the age of 2/4/6 and 15 months life, 
Balance of benefits and costs Acellular pertussis vaccine (aP) Whole cell pertussis vaccine (wP)
Quality of evidence for benefits Highly effective Highly effective
Intervention effects • Primary series reduces the risk of 
 severe pertussis
• Lower incidence of adverse reactions 
than with wP vaccine [96, 97]
• Primary series reduces the risk of 
severe pertussis
• Primary series not associated with 
serious adverse effects
Duration of protection • May decline before 6 years • At least 6 years
• Longer than that induced by aP [98]
Resource implications • Significantly more expensive than the 
wP vaccine
• Significantly less expensive than 
the aP vaccine
Table 1. WHO evidences to pertussis vaccines [95].
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which are about 250 million doses annually. Over the past 20 years, the Institute has been 
investigating new pertussis vaccines, less reactogenic and at low cost [104].
Although effective, wP vaccines contain a significant amount of lipooligosaccharide (LOS), 
an endotoxin of Gram-negative outer membrane that may be involved in the local and sys-
temic adverse vaccine reactions. The introduction of procedures that increase the safety of 
wP vaccines maintaining its effectiveness remains a very important aspect, especially for 
developing countries that do not have access to currently available aP vaccines. In this sense, 
a whole cell pertussis vaccine was developed with low endotoxicity (Plow) obtained by chem-
ical extraction of the LOS fraction from the outer membrane of the bacterial cell [105]. This 
vaccine was evaluated as DTwP vaccine, combined with tetanus and diphtheria toxoids in 
a Phase I field trial in infants, showing to be less reactogenic and equally immunogenic and 
protective as the traditional DTP vaccine [106].
Many developed countries using acellular pertussis vaccines in infancy have introduced a 
booster dose for adolescents [107], preventing the carrier state, an attempt to block the spread 
of the disease to infants not immunized or with incomplete immunization schedule. Due to its 
low reactogenicity, the Plow vaccine may possibly be introduced into the vaccination sched-
ule for immunization of adolescents and young adults in Brazil, an important epidemiological 
contribution to reducing the circulation of B. pertussis.
Preliminary studies in our laboratory have shown that the Plow is able to protect mice against 
B. parapertussis (unpublished data), suggesting an important role in the control of this pathogen, 
which has not been reached by vaccination with acellular pertussis vaccines [17, 90, 91, 108, 109].
The cost to produce the Plow vaccine is the same as the conventional whole cell pertussis 
vaccine, which makes its use feasible in developing countries, such as Brazil [89, 110], as an 
alternative for use in different strategies for the control of pertussis resurgence, including vac-
cination of adolescents and adults, due to their lower reactogenicity.
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